- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05362110
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (HM_APOLLO)
September 24, 2023 updated by: Hanmi Pharmaceutical Company Limited
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HCP1803 in patients with essential hypertension
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
361
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jin-A Jung, Ph.D.
- Phone Number: 82-2-410-9038
- Email: jajung@hanmi.co.kr
Study Locations
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 10326
- Donggguk University Ilsan Hospital
-
Contact:
- Moo-Yong Rhee, M.D., Ph.D.
- Phone Number: 82-31-961-5775
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
- mean sitSBP <180 mmHg and mean sitDBP < 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
- 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
- Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP < 180 mmHg and 60 mmHg ≤ mean sitDBP < 110 mmHg at Visit 2
Exclusion Criteria:
- Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
- Orthostatic hypotension with symptoms within 3 months prior to visit 1.
- Secondary hypertensive patient or suspected to be
- Uncontrolled diabetes mellitus(HbA1c > 9%) or type I diabetes mellitus
- Active gout or hyperuricemia (uric acid ≥ 9mg/dL)
- Severe heart disease or severe neurovascular disease
- Moderate or malignant retinopathy
- Clinically significant hematological finding
- Severe renal diseases (eGFR<30mL/min/1.73m2)
- Severe or active hepatopathy (AST or ALT ≥ 3 times of normal range)
- Hypokalemia or Hyperkalemia(K<3.5mmol/L or K ≥ 5.5mmol/L)
- Hyponatremia or Hypernatremia(Na<135mmol/L or Na ≥ 155mmol/L)
- Hypercalcemia
- History of malignancy tumor
- History of autoimmune disease
- History of alcohol or drug abuse
- Positive to pregnancy test, nursing mother, intention on pregnancy
- Considered by investigator as not appropriate to participate in the clinical study with other reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
HCP1803-3
|
Take it once daily for 8 weeks orally.
Placebo drug.
Take it once daily for 8 weeks orally.
|
Active Comparator: Active Comparator
RLD2002
|
Placebo drug.
Take it once daily for 8 weeks orally.
Take it once daily for 8 weeks orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in sitting systolic blood pressure
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in sitting systolic blood pressure
Time Frame: baseline, 4 weeks
|
baseline, 4 weeks
|
Change from baseline in sitting distolic blood pressure
Time Frame: baseline, 4 weeks, 8 weeks
|
baseline, 4 weeks, 8 weeks
|
Proportion of subjects achieving blood pressure control
Time Frame: 4 weeks, 8 weeks
|
4 weeks, 8 weeks
|
Blood pressure response rate
Time Frame: 4 weeks, 8 weeks
|
4 weeks, 8 weeks
|
Treatment response rate
Time Frame: 4 weeks, 8 weeks
|
4 weeks, 8 weeks
|
Change from baseline in pulse pressure
Time Frame: baseline, 4 weeks, 8 weeks
|
baseline, 4 weeks, 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Moo-Yong Rhee, M.D., Ph.D., Donggguk University Ilsan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 16, 2022
Primary Completion (Actual)
June 5, 2023
Study Completion (Actual)
June 5, 2023
Study Registration Dates
First Submitted
May 1, 2022
First Submitted That Met QC Criteria
May 1, 2022
First Posted (Actual)
May 5, 2022
Study Record Updates
Last Update Posted (Actual)
September 26, 2023
Last Update Submitted That Met QC Criteria
September 24, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM-APOLLO-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on HCP1803-3
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Eastern Mediterranean UniversityCompletedOverweight and ObesityCyprus
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Aortic Stenosis, SevereUnited States, Canada
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknown
-
Edwards LifesciencesActive, not recruitingAortic Valve Stenosis | Aortic Stenosis, CalcificUnited States, Australia, Japan, Canada, Netherlands, Switzerland
-
University of AarhusSteno Diabetes Center Aarhus, Aarhus University Hospital, Denmark; Department...CompletedKetosis | Postprandial Hyperglycemia | Glucose Metabolism Disorders (Including Diabetes Mellitus)Denmark
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Sheffield Children's NHS Foundation TrustUniversity of SheffieldCompletedAcute BronchiolitisUnited Kingdom
-
UNICANCERCompleted